Viewing Study NCT04390295


Ignite Creation Date: 2025-12-24 @ 2:11 PM
Ignite Modification Date: 2026-01-01 @ 3:11 AM
Study NCT ID: NCT04390295
Status: UNKNOWN
Last Update Posted: 2020-05-15
First Post: 2018-09-18
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Organization:

Study Overview

Official Title: Clinical Trial to Evaluate the Efficacy and Safety of SHR3824 Combined With Metformin in Metformin Monotherapy Poorly Glycemic Controlled Chinese Type 2 Diabetic Patients
Status: UNKNOWN
Status Verified Date: 2020-05
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to obtain information on efficacy and safety of SHR3824 with metformin over 24 weeks and 52 weeks in metformin monotherapy poorly glycemic controlled chinese Type 2 Diabetes. Efficacy and safety will be evaluated by comparing the effect of SHR3824 with metformin to placebo with metformin when given in oral doses.
Detailed Description: A phase III clinical study on efficacy and safety of SHR3824 combined with metformin for type 2 diabetes with poor glucose control in metformin monotherapy (multicenter, randomized, double-blind, placebo-parallel control). The 450 subjects received at least eight weeks of metformin monotherapy at a steady dose of 1500 mg or more before screening.

Evaluation of efficacy: compared with the group of placebo combined with metformin, HbA1c, fasting plasma glucose, postprandial plasma glucose, fasting body weight and blood pressure changes in the SHR3824 with metformin group

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: